brolucizumab sold trade name beovu among others humanized singlechain antibody fragment treatment neovascular wet agerelated macular degeneration common side effects reduced visual acuity cataract clouding lens eye conjunctival haemorrhage bleeding front eye vitreous floaters spots serious side effects blindness endophthalmitis infection inside eye retinal artery occlusion blockage artery retina retinal detachment separation retina back brolucizumab designed attach block substance called vascular endothelial growth factor vegfa protein makes blood vessels grow leak fluid blood damaging macula blocking vegfa brolucizumab reduces growth blood vessels controls leakage brolucizumab us food drug administration fda approved ophthalmology brolucizumab successfully completed phase iii development wet agerelated macular degeneration amd meeting primary efficacy endpoint noninferiority aflibercept mean change best corrected visual acuity bcva baseline week furthermore brolucizumab demonstrated superiority aflibercept key secondary endpoint measures disease activity wet amd leading cause blindness two headtohead pivotal phase iii october novartis announced us food drug administration fda approved brolucizumab injection treatment wet beovu first fda approved antivegf offer greater fluid resolution versus aflibercept ability maintain eligible wet amd patients threemonth dosing interval immediately threemonth loading verification uncompromised efficacymedical citation needed fda approved beovu based evidence two clinical trials trial trial patients years old wet amd trials conducted sites united states canada central south america european countries israel turkey australia new zealand japan south korea singapore taiwan brolucizumab approved use european union february february american society retina specialists reported side effects drug specifically cases retinal vasculitis reported beovu patients cases occlusive retinal vasculitis lead vision novartis responded statement standing behind efficacy june fda approved updated beovu label included additional safety information specifically including characterization adverse events retinal vasculitis retinal vascular occlusion part spectrum intraocular inflammation observed hawk harrier clinical trials noted original prescribing brolucizumab international nonproprietary name inn united states adopted name nonophthalmology indications investigation name preclinical development kaposi httpsenwikipediaorgwikibrolucizumab